U.S. markets open in 4 hours 58 minutes
  • S&P Futures

    3,917.25
    -5.25 (-0.13%)
     
  • Dow Futures

    31,947.00
    +31.00 (+0.10%)
     
  • Nasdaq Futures

    13,216.00
    -86.00 (-0.65%)
     
  • Russell 2000 Futures

    2,297.50
    +12.40 (+0.54%)
     
  • Crude Oil

    63.52
    +0.30 (+0.47%)
     
  • Gold

    1,787.40
    -10.50 (-0.58%)
     
  • Silver

    27.99
    +0.06 (+0.22%)
     
  • EUR/USD

    1.2219
    +0.0051 (+0.42%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.92
    -1.19 (-5.15%)
     
  • GBP/USD

    1.4165
    +0.0024 (+0.17%)
     
  • USD/JPY

    106.1120
    +0.2300 (+0.22%)
     
  • BTC-USD

    49,138.45
    -1,505.76 (-2.97%)
     
  • CMC Crypto 200

    981.30
    -13.36 (-1.34%)
     
  • FTSE 100

    6,687.48
    +28.51 (+0.43%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

One stock that might be an intriguing choice for investors right now is Global Blood Therapeutics, Inc. GBT. This is because this security in the Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Biomedical and Genetics space as it currently has a Zacks Industry Rank of 11 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Global Blood Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm???s prospects in both the short and long term.

Global Blood Therapeutics, Inc. Price and Consensus

Global Blood Therapeutics, Inc. Price and Consensus
Global Blood Therapeutics, Inc. Price and Consensus

Global Blood Therapeutics, Inc. price-consensus-chart | Global Blood Therapeutics, Inc. Quote

In fact, over the past month, current quarter estimates have narrowed from a loss of $1.40 per share to a loss of $1.22 per share, while current year estimates have narrowed from a loss of $5.49 per share to a loss of $4.61 per share. This has helped GBT to earn a Zacks Rank #2 (Buy), further underscoring the company???s solid position. You can see the complete list of today???s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Global Blood Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don???t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Global Blood Therapeutics, Inc. (GBT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research